News

Virnext congratulates AIS Biotech on successfully raising €1.5 million to advance the development of its innovative therapies for infectious diseases. This funding will support the preclinical development of GlycoFlu, their novel drug candidate for influenza, and strengthen their technological platform for sugar-based bioproduction, designed to target additional pathogens. This milestone reflects the confidence of AIS Biotech’s partners and investors in the company’s strategy and technolog...

RESPIVIR and its technological research platform Virnext are very proud to be partners in two public–private R&D consortia focused on respiratory viral infectious diseases. #SHIELD Project The #SHIELD project aims to revolutionize the control of airborne infectious risk in hospitals by developing innovative, deployable, and more sustainable controlled environment solutions. It is part of a broader effort to support healthcare infrastructure by: improving responsiveness in the eve...

We will be taking part in the 4th edition of Tech365 Meetings, the 100% online annual event dedicated to innovation and technology transfer, on 1 July 2025! Tech365 provides virnext with the opportunity to discover breakthrough technologies emerging from public research and deeptech, while exploring potential avenues for technological synergies and translational research partnerships. See you on 1 July, for one-to-one virtual meetings....

This study aimed to characterize the infection kinetics and long-term epithelial innate responses to IAV H1N1, RSV-A, and SARS-CoV-2 in a human nasal epithelial model (MucilAir™) cultured at air-liquid interface. Replication, tissue integrity, host gene expression, and epithelium morphology were assessed up to 28 days post-infection (dpi). Our results show that IAV, RSV, and SARS-CoV-2 trigger distinct, long-lasting epithelial responses in the absence of immune cells, highlighting virus-specif...

Virnext congratulates VirexpR on the inauguration of its modular biosafety laboratory, IMePOD, in the Auvergne-Rhône-Alpes region. This new facility enhances their ability to advance research on airborne infectious contamination and indoor air quality across key sectors including transportation, healthcare, pharmaceutical, agri-food and animal husbandry. The inauguration, presided over by Catherine Staron, Vice-President of the Auvergne-Rhône-Alpes Region, brought together academic and indu...

Respiratory Syncytial Virus (RSV) is one of the leading causes of severe respiratory infections in young children. In France, bronchiolitis is estimated to affect nearly 30% of infants under 2 years of age, representing around 480,000 cases per year, including 35,000 hospitalizations each winter. Two studies conducted in mainland France by Santé publique France during the 2023–2024 winter season confirmed the real-world effectiveness of #nirsevimab (BEYFORTUS®; Sanofi/AstraZeneca) in prevent...

We are proud to announce that ANTIVIRESPIR is one of the 9 excellence projects selected by an international expert panel as part of the 2024 PEPR MIE Call for Projects, and approved for funding by the General Secretariat for Investment, following a decision by the Prime Minister. The ANTIVIRESPIR project aims to significantly scale up the national infrastructure #Virocrib (@CNRS Biology) by partnering with the #GAVO consortium (Generation of Original Antivirals, @CNRS Chemistry) and the ChemBioF...

Our mini-review entitled « In vitro models to study viral-induced asthma exacerbation: a short review for a key issue » has been published in Frontiers In Allergy !Asthma is a major health problem worldwide, which can be associated with morbidity and mortality. Respiratory viral infections are one of the most important causes of asthma exacerbation, but the underlying virus-induced mechanisms are incompletely described.To meet this urgent need and develop new efficient therapies, it is neces...

Successful collaboration with Epithelix in the characterization of AlveolAir™, a new primary 3D human alveolar model designed to advance respiratory virus research and antiviral development.The study described an innovative in vitro alveolar co-culture system at the air–liquid interface, developed by Epithelix, which maintains human primary alveolar type I and II epithelial and endothelial cells with a functional barrier for over 30 days.We characterized AlveolAir™ as a relevant system for...

Our study "Host-targeted repurposed diltiazem enhances the antiviral activity of direct acting antivirals against Influenza A virus and SARSCOV2" has been published in Antiviral Research.Influenza and SARSCoV2 infections are major public health threat with recurrent emergence and dissemination of variant strains carrying mutations resulting in suboptimal vaccine protection and/or reduced efficacy of current limited therapeutic arsenal. In this context, host-targeted approaches constitute a promi...